Neil Gallagher, M.D., Ph.D.

Neil Gallagher, M.D., Ph.D.

President, Head of Research & DevelopmentatSyndax Pharmaceuticals· In proxies 2023–2024

Pay in FY2024-25% from the year before · Syndax Pharmaceuticals stock -38.8% the same year

Neil Gallagher, M.D., Ph.D. was paid $2.9M in FY2024 (Dec), down 25%. Syndax Pharmaceuticals stock fell 38.8% that year.

Pay$100 in the stock at the end of FY22 → $52
Pay is from the Summary Compensation Table of each Syndax Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Syndax PharmaceuticalsPublic company · 3 yr
    • President, Head of Research & Development2023 – Present · 3 yrStock in role -39%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?